Pharmaceutical Data Collaboration Between Canada’s Drug Agency and CIHI

By João L. Carapinha

January 15, 2025

Canada’s Drug Agency and the Canadian Institute for Health Information signed an agreement to improve pharmaceutical data collaboration.

Agreement and Collaboration

Canada’s Drug Agency (CDA-AMC) and the Canadian Institute for Health Information (CIHI) have signed a 3-year agreement aimed at enhancing pharmaceutical data and analytics in Canada.

Objectives

The primary goal of this agreement is to strengthen the foundation of drug data and analytics across Canada. This will be achieved by leveraging the strengths of both organizations.

Scope of Work

The collaboration will focus on expanding CIHI’s pharmaceutical data holdings to support advanced analytics. These analytics will improve drug access, safety, and patient health outcomes.

Work Streams

The agreement aligns with the three new work streams announced by the federal government in December 2023 for Canada’s Drug Agency:
– Appropriate use of medications
– Data and analytics
– System coordination and alignment.

Stakeholder Involvement

The partnership will involve collaboration with federal, provincial, and territorial governments, as well as other key stakeholders to advance CIHI’s Pharmaceutical Roadmap.

Impact

This collaboration is expected to enhance the overall pharmaceutical system in Canada by providing better data-driven insights, reducing inefficiencies, and improving health outcomes.

This agreement reflects a broader effort to improve coordination, data collection, and analytical capabilities within Canada’s pharmaceutical sector. It aligns with the broader objectives of the Canadian Drug Agency Transition Office and national pharmacare initiatives. The pharmaceutical data collaboration effort is critical for achieving these goals.

Reference url

Recent Posts

Simponi Pediatric Approval: FDA Grants First Pediatric Indication for Ulcerative Colitis Treatment

By HEOR Staff Writer

October 9, 2025

The U.S. Food and Drug Administration has granted Simponi pediatric approval for Johnson & Johnson's Simponi (golimumab), which is intended for children with moderately to severely active ulcerative colitis who weigh at least 15 kg. This historic approval is backed by data from the PURSUIT pr...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS
The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...